Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

Lenalidomide-utilizing self-assembled immunogenic cell death-inducing heparin/doxorubicin nanocom...

Lenalidomide-utilizing self-assembled immunogenic cell death-inducing heparin/doxorubicin nanocomplex for anticancer immunotherapy  ScienceDirect.com

Lenalidomide Skin Rash May be Marker for Better Survival in Multiple Myeloma - Hematology Advisor

Lenalidomide Skin Rash May be Marker for Better Survival in Multiple Myeloma  Hematology Advisor

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma -...

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Fo...

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT  OncLive

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leuk...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leukemia  Nature

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple ...

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma  Pharmacy Times

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma  OncLive

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma...

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study  ScienceDirect.com

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with h...

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial  Nature

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma | Scientific Reports  Nature

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Emerges as a SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgro...

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study | Leukemia  Nature

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transpla...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial  Nature

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and...

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation  Nature

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial | Blood Cancer Journal  Nature

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells - Sc...

Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells  ScienceDirect.com

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma  OncLive

The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery syste...

The lenalidomide derivative loaded and quercetin modified MIL-100 based novel drug delivery system for breast cancer treatment  ScienceDirect.com

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineli...

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial  The Lancet

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments - CancerNetwork

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments  CancerNetwork

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly di...

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease | Scientific Reports  Nature

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma - The ASCO Post

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma  The ASCO Post

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multip...

Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry  Nature

Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatm...

Periorbital necrobiotic xanthogranuloma resolved with three years of systemic lenalidomide treatment  ScienceDirect.com

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma - Onc...

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma  OncLive

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients - European...

Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients  European Respiratory Society

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with t...

Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients | Blood Cancer Journ  Nature

Near-infrared light controlled protein degradation by photo-caged lenalidomide and pomalidomide -...

Near-infrared light controlled protein degradation by photo-caged lenalidomide and pomalidomide  ScienceDirect.com

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) vers...

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, ran  Frontiers

New breakthrough combats lenalidomide resistance in multiple myeloma - NUS - National University ...

New breakthrough combats lenalidomide resistance in multiple myeloma  NUS - National University of Singapore

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelod...

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial  Nature

Lenalidomide use in multiple myeloma (Review) - Spandidos Publications

Lenalidomide use in multiple myeloma (Review)  Spandidos Publications

Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patie...

Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma  BMC Pulmonary Medicine

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells - Science ...

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells  Science | AAAS

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradat...

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation  Nature

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - New England Journ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  New England Journal of Medicine

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma - New England Journa...

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma  New England Journal of Medicine

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America - New England Jour...

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America  New England Journal of Medicine

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomi...

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma  Nature

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma:...

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial  Nature

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (...

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma | Blood Cancer Journal  Nature

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide -...

Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide  Nature

FDA Approves New Use for Lenalidomide in Multiple Myeloma - National Cancer Institute (.gov)

FDA Approves New Use for Lenalidomide in Multiple Myeloma  National Cancer Institute (.gov)

Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunothera...

Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy  ScienceDirect.com

Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymor...

Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1  Nature

Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into R...

Lenalidomide Stabilizes Protein–Protein Complexes by Turning Labile Intermolecular H-Bonds into Robust Interactions  ACS Publications

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma - New England Journal of Medicine

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma  New England Journal of Medicine

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide - Science | AAAS

Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide  Science | AAAS

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal func...

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study  Nature

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - New England Journal of Medi...

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  New England Journal of Medicine

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma - New England Journ...

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma  New England Journal of Medicine

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma - New England Journal o...

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma  New England Journal of Medicine

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phas...

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study  Nature

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in ...

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)  Nature

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma - New England Journal of M...

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma  New England Journal of Medicine

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma - New England Journal ...

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma  New England Journal of Medicine

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide - Nature

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide  Nature

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalido...

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia  Nature

Lenalidomide long-term neurotoxicity - Neurology® Journals

Lenalidomide long-term neurotoxicity  Neurology® Journals

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using ...

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4  Nature

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients...

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial  The Lancet

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patient...

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial | Blood Cancer Journal  Nature

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma - New England Journal of Me...

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma  New England Journal of Medicine

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk ne...

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma  ScienceDirect.com

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Pat...

Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma  Frontiers

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction ...

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials  ScienceDirect.com

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple...

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA | Leukemia  Nature

Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospectiv...

Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study  The Lancet

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q)...

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial  The Lancet

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma - New England Journal of M...

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma  New England Journal of Medicine

Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19...

Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19  OncLive

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenali...

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment  Nature

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (M...

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial  The Lancet

Lenalidomide and Pomalidomide: Immunomodulating Drug Therapies in Multiple Myeloma - Pharmacy Times

Lenalidomide and Pomalidomide: Immunomodulating Drug Therapies in Multiple Myeloma  Pharmacy Times

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma - New England Journal o...

Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma  New England Journal of Medicine

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a...

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study  The Lancet

Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Before Autologous Stem Cell Tran...

Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy Before Autologous Stem Cell Transplant for Multiple Myeloma  National Institutes of Health (NIH) | (.gov)

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem...

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice  JCI.org

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma - New England Journal of Me...

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma  New England Journal of Medicine

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase - Nature

Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase  Nature

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma - New England Journ...

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma  New England Journal of Medicine

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms - Science...

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms  ScienceDirect.com

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed in...

Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial  The Lancet

Thalidomide Vs Lenalidomide for Newly Diagnosed Multiple Myeloma - Hematology Advisor

Thalidomide Vs Lenalidomide for Newly Diagnosed Multiple Myeloma  Hematology Advisor

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 55...

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial  ScienceDirect.com

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS - Nature

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS  Nature

Using Lenalidomide and Pomalidomide in RRMM Management - AJMC

Using Lenalidomide and Pomalidomide in RRMM Management  AJMC

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma - New England Journal...

Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma  New England Journal of Medicine

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving c...

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4  Frontiers

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffu...

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study  The Lancet

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearrang...

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients | Blood Cancer Journal  Nature

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a mult...

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study  The Lancet

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 ...

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age  Nature

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma - New England Journal of Medicine

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma  New England Journal of Medicine